306 related articles for article (PubMed ID: 16496485)
21. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
22. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
[TBL] [Abstract][Full Text] [Related]
23. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience and management considerations with long-acting risperidone.
Parellada E
Curr Med Res Opin; 2006 Feb; 22(2):241-55. PubMed ID: 16466596
[TBL] [Abstract][Full Text] [Related]
25. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
Chue PS; Heeg B; Buskens E; van Hout BA
Pharmacoeconomics; 2005; 23 Suppl 1():62-74. PubMed ID: 16416762
[TBL] [Abstract][Full Text] [Related]
26. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
Bhanji NH; Chouinard G; Margolese HC
Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
[TBL] [Abstract][Full Text] [Related]
27. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
Zeidler J; Mahlich J; Greiner W; Heres S
Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
[TBL] [Abstract][Full Text] [Related]
30. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
Laux G; Heeg B; van Hout BA; Mehnert A
Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
32. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
[TBL] [Abstract][Full Text] [Related]
33. Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claim-based database in Taiwan.
Chang HC; Tang CH; Tsai SJ; Yen FC; Su KP
J Clin Psychiatry; 2009 Jan; 70(1):141. PubMed ID: 19238691
[No Abstract] [Full Text] [Related]
34. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
[TBL] [Abstract][Full Text] [Related]
35. Health resource utilization associated with switching to risperidone long-acting injection.
Young CL; Taylor DM
Acta Psychiatr Scand; 2006 Jul; 114(1):14-20. PubMed ID: 16774656
[TBL] [Abstract][Full Text] [Related]
36. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
[TBL] [Abstract][Full Text] [Related]
37. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
Carswell C; Wheeler A; Vanderpyl J; Robinson E
Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
[TBL] [Abstract][Full Text] [Related]
38. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.
Dilla T; Möller J; O'Donohoe P; Álvarez M; Sacristán JA; Happich M; Tockhorn A
BMC Psychiatry; 2014 Dec; 14():298. PubMed ID: 25438678
[TBL] [Abstract][Full Text] [Related]
39. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
40. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone.
Vieta E; Nieto E; Autet A; Rosa AR; Goikolea JM; Cruz N; Bonet P
World J Biol Psychiatry; 2008; 9(3):219-24. PubMed ID: 18609430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
